Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

naporafenib (ERAS-254)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Erasca, Novartis

Drug class:

BRAF inhibitor, pan-RAF inhibitor, cRAF inhibitor

Related drugs:

‹

›

NRAS mutation	Melanoma	NRAS mutation	Melanoma	trametinib + ERAS-254 Sensitive: B - Late Trials trametinib + ERAS-254 Sensitive : B	trametinib + ERAS-254 Sensitive: B - Late Trials trametinib + ERAS-254 Sensitive : B
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	ERAS-254 Sensitive: C2 – Inclusion Criteria ERAS-254 Sensitive : C2	ERAS-254 Sensitive: C2 – Inclusion Criteria ERAS-254 Sensitive : C2
BRAF G466A	Non Small Cell Lung Cancer	BRAF G466A	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	NBL-001 + ERAS-254 Sensitive: D – Preclinical NBL-001 + ERAS-254 Sensitive : D	NBL-001 + ERAS-254 Sensitive: D – Preclinical NBL-001 + ERAS-254 Sensitive : D